SAN DIEGO, December 8, 2020-- RayzeBio, Inc., which launched this year to develop a broad pipeline of targeted radiopharmaceuticals against validated solid tumor targets, today announced a $105 million Series B financing led by Venrock Healthcare Capital Partners (VHCP) alongside new investors OrbiMed, Redmile Group, Viking Global Investors, Logos Capital, Cormorant Asset Management, LifeSci Venture Partners, Alexandria Venture Investments and others. Also participating were existing investors from RayzeBio’s $45 million Series A financing, including venBio Partners, Versant Ventures and Samsara BioCapital.